Market Pulse: Yesterday’s session saw wild swings as thin holiday liquidity amplified dramatic moves across global equities.
Key Movers: Infosys ADRs erupted 40% in a classic short squeeze, Cytokinetics clinched FDA approval for MYQORZO™, and BP’s CEO shake-up reignited Shell takeover rumors.
Macro & Politics: President Trump’s fresh health orders and marijuana schedule downgrade rattled healthcare and cannabis stocks alike.
What’s Next: Watch for renewed momentum plays when US markets reopen with volume pick-up.
What everyone’s missing is that Infosys’ 40% surge isn’t real strength—it’s a glaring symptom of ultra-thin books over the holidays getting yanked around by the smallest retail army. You think that kind of move shows conviction? It’s a buffoon show until sweat-equity traders get burned.
At first glance, a biotech FDA win and oil-sector merger chatter seem miles apart, but they’re both rides on deregulation’s coattails. From MYQORZO™ clearing the FDA to BP’s CEO exit stirring Shell deal dreams, the common thread is policy tailwinds removing barriers—maddening for anyone clinging to old-guard strategies.
Actionable takeaway: lean into catalyst runs but respect risk. Keep positions nimble, set stop-losses, and target specific events—not the entire tape. This market rewards precision, not wishful thinking.
Explainer: Why Infosys ADRs jumped 40% and why the NYSE halted trading
Infosys ADRs surged 40% on the NYSE, hitting a 52-week high of $30 and triggering two trading halts. Analysts cite a combination of a short squeeze, automated trading glitches, and low holiday liquidity. Infosys clarified there were no material developments b…
Cytokinetics Announces FDA Approval of MYQORZO (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Funct
Cytokinetics Announces FDA Approval of MYQORZO (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and SymptomsCytokinetics Cytokinetics heart drug wins FDA approval, the biotech’s fi…
Cytokinetics announces FDA approval of Myqorzo
See the rest of the story here. thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual investors, professional money managers, active traders, and corpor…
Cytokinetics Announces FDA Approval of MYQORZO™ (aficamten) for the Treatment of Adults with Symptomatic Obstructive Hypertrophic Cardiomyopathy to Improve Functional Capacity and Symptoms
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM FDA Approval Based on Results of…
One specific coin aligns perfectly with Trump's regulatory reforms and vision for America's financial dominance in the digital age.
Get the name of the ideal crypto for Trump's presidency for just $3 before his policies drive prices higher.
Trump Green–Lights Marijuana Drug Schedule Change, But Stops Short of Federally Legalizing Weed
In time for Christmas, Trump pushes marijuana down from the “naughty list” of Schedule I to the less-restricted “nice list” of Schedule III. The post Trump Green–Lights Marijuana Drug Schedule Change, But Stops Short of Federally Legalizing Weed first appeare…
Is MEDVi the Best GLP-1 Supplier for 2026? Platform Lists Compounded Semaglutide at $179/Month With No Contract Ahead of Weight Loss Season
MEDVi lists compounded GLP-1 injections at $179 first month, $299 refills as 100,000+ patients seek affordable semaglutide ahead of 2026 New Year….
BP CEO Shake-Up Reopens Talk of a Shell Megadeal
The appointment of Meg O’Neill as BP's chief executive officer, replacing Murray Auchincloss, is a momentous milestone in the oil industry. When O’Neill takes over on April 1, 2026, she will become the first woman ever to lead a Big Oil company. But O’Neill’s…
BP CEO Shake-Up Reopens Talk of a Shell Megadeal
Timing adds fuel to the rumors, as Shell’s six-month restriction on bidding for BP expires on December 26, reopening the door to potential takeover talks.
Micron Says ‘We Are More Than Sold Out.’ Should You Buy MU Stock After Earnings?
Micron stock is up over 200% over the last 12 months and trades at a compelling valuation, given its stellar growth estimates.
Alert: The DeFi Token Set to Explode as Markets Recover
This isn't speculation – this platform's role is so essential to crypto's financial system that its current price defies all logic. Just Released: The DeFi token set for massive gains as markets heat up – only $3!
In cahoots: Ex-FDA commissioners against higher vaccine standards took $6 million from COVID vax makers
‘Old guard' bashed Trump appointees for expecting most new approvals will need randomized clinical trials
Other Barks and Bites for Friday, December 19: UK High Court Defines Scope of RAND Obligations; Senators Welch and Blackburn Introduce Copyright Reform Bill; and Global Value of Music Copyright Doubles Since 2015
This week in Other Barks and Bites: Will Page’s Global Value of Music Copyright report shows that industry revenues have doubled since 2015 despite slowing growth as pandemic impacts are no longer felt; the Federal Circuit rules that it lacks jurisdiction to …
Decrypt’s 2025 Project of the Year: Hyperliquid
Hyperliquid, a venue for high-risk leveraged trading on volatile assets, captured the attention of the crypto industry like no other project this year.
Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement
Financing included participation by healthcare-dedicated investors alongside existing shareholders TORONTO, Dec. 19, 2025 (GLOBE NEWSWIRE) — Profound Medical Corp. (Nasdaq:PROF; TSX:PRN) (“Profound” or the “Company”) today announced the sale of 5,142,857 comm…
Profound Medical Corp. Announces Pricing of up to $40 Million Financing Comprised of a $36 Million Registered Direct Offering and a Subsequent $4 Million Private Placement
Financing included participation by healthcare-dedicated investors alongside existing shareholders Financing included participation by healthcare-dedicated investors alongside existing shareholders
EXPERT: “Every American Investor Could Soon Become a Millionaire”
Not by finding the next NVIDIA or Bitcoin, but by owning a simple index fund. It sounds impossible. Yet it happened – just a short time ago. Now a legendary figure says: “Brace yourselves. It's about to happen here, in America. But fair warning – it could be the worst thing that ever happens to you.” This story has received little coverage in the press. But if history repeats, it could bump tens of millions of Americans into a 7-figure net worth practically overnight. Click here for the full story.